Schrödinger, Inc. (SDGR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 108 | 138 | 181 | 217 | 208 | 256 | 259 | 243 |
| Operating profit | $m | -167 | -153 | ||||||
| Net profit | $m | -24 | -100 | -149 | 41 | -187 | -103 | -54 | -118 |
| EPS reported | $ | -1.41 | -0.74 | ||||||
| Operating cashflow per share | $ | 0.19 | -0.39 | ||||||
| Capex per share | $ | 0.02 | 0.05 | ||||||
| FCF per share | $ | 0.17 | -0.43 | ||||||
| Free cash flow | $m | 12 | -32 | ||||||
| Net debt | $m | -379 | -414 | ||||||
| Book value equity | $m | 364 | 329 | ||||||
| Book value per share | $ | 4.96 | 4.34 | ||||||
| Number of shares | m | 73.44 | 75.77 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.61 | 3.99 | ||||||
| P/S LTM | x | 5.13 | 5.07 | ||||||
| P/FCF LTM | x | 105.42 | -40.45 | ||||||
| EV/EBITDA LTM | x | -12.38 | -25.98 | ||||||
| EV/Sales LTM | x | 4.66 | 4.38 | ||||||
| Earnings Yield LTM | % | -7.86% | -4.13% | ||||||
| FCF Yield | % | +0.95% | -2.47% | ||||||
| Quality | |||||||||
| ROE | % | -28.37% | -16.37% | ||||||
| ROIC | % | -30.16% | -31.77% | ||||||
| Operating margin | % | -65.23% | -59.24% | ||||||
| Gross margin | % | +55.74% | +56.87% | ||||||
| FCF/Sales | % | +4.87% | -12.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +23.29% | +24.81% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.11 | -0.30 | ||||||
| Net Debt/EBITDA | x | 1.26 | 3.92 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +1.25% | 0.00% | ||||||
| Net debt/Equity | x | -1.04 | -1.26 | ||||||
| Gross debt/equity | x | 0.30 | 0.33 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free